How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

26,588 results for

Obesity Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Ileal interposition coupled with duodenal diverted sleeve gastrectomy versus standard medical treatment in type 2 diabetes mellitus obese patients: long-term results of a case-control study. (PubMed)

Ileal interposition coupled with duodenal diverted sleeve gastrectomy versus standard medical treatment in type 2 diabetes mellitus obese patients: long-term results of a case-control study. Randomized controlled trials have demonstrated that bariatric surgery is effective in obtaining remission of type 2 diabetes mellitus (T2DM) in obese patients, yet no data exist in the literature from prospective studies with ileal interposition with duodenal diversion sleeve gastrectomy (II-DD-SG). The aim (...) of this case-control study is to investigate if II-DD-SG is superior to medical treatment in T2DM obese patients.Thirty obese patients (BMI > 30) affected by T2DM were recruited for surgery (II-DD-SG) between 2008 and 2011 and were matched with an equal control group which received standard medical treatment. Anthropometric measures, glucose metabolism, cardiovascular risk factors were determined baseline and during follow-up. The primary end point was T2DM remission; reduction of body weight, BMI

2018 Surgical endoscopy

42. Laparoscopic Conversion of a Vertical Banded Gastroplasty to a Sleeve Gastrectomy in a Morbidly Obese Patient with a Complicated Medical History. (PubMed)

Laparoscopic Conversion of a Vertical Banded Gastroplasty to a Sleeve Gastrectomy in a Morbidly Obese Patient with a Complicated Medical History. We present our technique for performing a laparoscopic conversion of vertical banded gastroplasty (VBG) to sleeve gastrectomy (SG) in a morbidly obese patient.A 58-year-old female with history of hypertension, diabetes, and morbid obesity (BMI 41). She had initially undergone an open VBG (BMI 58) and cholecystectomy (2002) and subsequently underwent

Full Text available with Trip Pro

2018 Obesity Surgery

43. Obesity: Are shared medical appointments part of the answer? (PubMed)

Obesity: Are shared medical appointments part of the answer? Shared medical appointments, in which a multidisciplinary team of healthcare providers meets with multiple patients in a group setting, may be an option for treating patients with obesity. To be effective, shared medical appointments need to address patients' nutrition, physical activity, appetite suppression, stress management, and sleep.Copyright © 2018 Cleveland Clinic.

Full Text available with Trip Pro

2018 Cleveland Clinic Journal of Medicine

44. Long-term mortality in obese subjects undergoing malabsorptive surgery (biliopancreatic diversion and biliointestinal bypass) versus medical treatment. (PubMed)

Long-term mortality in obese subjects undergoing malabsorptive surgery (biliopancreatic diversion and biliointestinal bypass) versus medical treatment. Aim of this study was to analyze long-term mortality in obese patients receiving malabsorptive bariatric surgery (BS)[biliopancreatic diversion (BPD) and biliointestinal bypass (BIBP)] in comparison to medical treatment of obesity.Medical records of 1877 obese patients [body mass index (BMI) > 35 kg/m2, aged 18-65 years, undergoing BS (n = 472 (...) -surgical medical weight-loss treatment patients. Malabsorptive bariatric surgery significantly reduces long-term mortality in severely obese patients.

2018 International Journal of Obesity

45. Impact on weight and physical function of intensive medical weight loss in older adults with stage II and III obesity

Impact on weight and physical function of intensive medical weight loss in older adults with stage II and III obesity A 6-month pilot trial compared two strategies for weight loss in older adults with body mass indexes (BMIs) ≥35 kg/m(2) to assess weight loss response, safety, and impact on physical function.Twenty-eight volunteers were randomized to a balanced deficit diet (BDD) (500 kcal/day below estimated energy needs) or an intensive, low-calorie, meal replacement diet (ILCD, 960 kcal/day (...) ]) compared with BDD. There were no significant differences in change in physical function or adverse event frequency.Compared with a traditional BDD intervention, older adults who have severe obesity treated with intensive medical weight loss had greater weight loss and decreases in fat mass without a higher frequency of adverse events. In the short term, however, this did not translate into greater improvements in physical function.© 2016 The Obesity Society.

Full Text available with Trip Pro

2016 EvidenceUpdates

46. Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. (PubMed)

Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. Enoxaparin dosing recommendations for morbidly obese patients are lacking. Retrospective and observational studies reported goal anti-Xa levels with a median dose of 0.8 mg/kg using total body weight. Further studies are needed to determine if a more conservative dosing strategy is warranted.To determine if reduced dose enoxaparin was more effective than (...) standard dose at achieving goal anti-Xa levels in morbidly obese patients.A prospective, randomized, controlled study was conducted in patients with a body mass index (BMI) ≥40 kg/m2. Patients were randomized to standard (1 mg/kg) or reduced dose (0.8 mg/kg) enoxaparin every 12 hours. The primary outcome was the proportion of patients with an initial anti-Xa at goal (0.5-1.1 IU/mL).A total of 62 patients were enrolled and randomized to 1 mg/kg (n = 32) or 0.8 mg/kg (n = 30), and 54 patients completed

2018 The Annals of pharmacotherapy Controlled trial quality: uncertain

47. [Bariatric surgery versus medical therapy in the treatment of obesity]. (PubMed)

[Bariatric surgery versus medical therapy in the treatment of obesity]. 28421259 2018 09 06 2018 09 06 1433-0385 88 5 2017 May Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen Chirurg [Bariatric surgery versus medical therapy in the treatment of obesity]. 449-450 10.1007/s00104-017-0426-z Schröder W W Klinik für Allgemein-, Viszeral- und Tumorchirurgie, Universitätsklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. wolfgang.schroeder@uni-koeln.de. Bruns C C Klinik für (...) Allgemein-, Viszeral- und Tumorchirurgie, Universitätsklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. ger Comparative Study Journal Article Randomized Controlled Trial Bariatrische Chirurgie versus medikamentöse Therapie in der Behandlung der Adipositas. Germany Chirurg 16140410R 0009-4722 0 Glycated Hemoglobin A 0 hemoglobin A1c protein, human IM Diabetes Complications blood surgery Follow-Up Studies Gastric Bypass methods Glycated Hemoglobin A metabolism Humans Obesity, Morbid blood surgery

2018 Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen Controlled trial quality: uncertain

48. Effects of medical trainees' weight-loss history on perceptions of patients with obesity. (PubMed)

Effects of medical trainees' weight-loss history on perceptions of patients with obesity. Medical professionals often express weight-biased attitudes. Prior research suggests that people who overcome a challenge are critical of individuals who struggle to overcome the same challenge. Thus, medical trainees who have successfully achieved and maintained weight loss may express greater weight bias and more critical attitudes toward patients with obesity who fail to overcome these challenges.This (...) ). Female (but not male) trainees who had successfully lost weight expressed stronger weight-biased attitudes on the AFA scales than did those who had never lost weight (all p-values < 0.01).Medical trainees' personal success with weight loss and maintenance may negatively affect their perceptions of patients with obesity who struggle with weight management.© 2017 John Wiley & Sons Ltd and The Association for the Study of Medical Education.

2018 Medical education Controlled trial quality: uncertain

49. Dietary Management of Blood Glucose in Medical Critically Ill Overweight and Obese Patients: An Open-Label Randomized Trial. (PubMed)

Dietary Management of Blood Glucose in Medical Critically Ill Overweight and Obese Patients: An Open-Label Randomized Trial. Enteral nutrition (EN) increases hyperglycemia due to high carbohydrate concentrations while providing insufficient protein. The study tested whether an EN formula with very high-protein- and low-carbohydrate-facilitated glucose control delivered higher protein concentrations within a hypocaloric protocol.This was a multicenter, randomized, open-label clinical trial (...) with parallel design in overweight/obese mechanically ventilated critically ill patients prescribed 1.5 g protein/kg ideal body weight/day. Patients received either an experimental very high-protein (37%) and low-carbohydrate (29%) or control high-protein (25%) and conventional-carbohydrate (45%) EN formula.A prespecified interim analysis was performed after enrollment of 105 patients (52 experimental, 53 control). Protein and energy delivery for controls and experimental groups on days 1-5 were 1.2 ± 0.4

Full Text available with Trip Pro

2018 JPEN. Journal of parenteral and enteral nutrition Controlled trial quality: uncertain

50. A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. (PubMed)

A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. 29470327 2018 02 22 1873-233X 131 3 2018 Mar Obstetrics and gynecology Obstet Gynecol A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. 599 10.1097/AOG.0000000000002505 Cambos Sophie S Endocrinology-Nutrition Department, CHU Bordeaux, Hospital Haut-Leveque, Pessac, France. Rigalleau Vincent V Blanco Laurence L eng Journal Article United States

2018 Obstetrics and Gynecology Controlled trial quality: predicted high

51. A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity. (PubMed)

A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity. Weight gain and other metabolic sequelae of antipsychotic medications can lead to medication non-adherence, reduced quality of life, increased costs, and premature mortality. Of the approaches to address this, behavioral interventions are less invasive, cost less, and can result in sustained long-term benefits.We investigated behavioral weight (...) management interventions for veterans with mental illness across four medical centers within the Veterans Affairs (VA) Healthcare System.We conducted a 12-month, multi-site extension of our previous randomized, controlled study, comparing treatment and control groups.Veterans (and some non-veteran women) diagnosed with mental illness, overweight (defined as having a BMI over 25), and required ongoing antipsychotic therapy.One group received "Lifestyle Balance" (LB; modified from the Diabetes Prevention

2018 Journal of General Internal Medicine Controlled trial quality: uncertain

52. Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized (PubMed)

Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Treatment with basal insulin in Chinese populations is currently sub-optimal, with delayed initiation of insulin treatment and inadequate dose titration. Increasing the initial dose of insulin may be a practicable and effective solution (...) to the problem of titration. A higher initial dose will be helpful for patients to achieve the blood glucose target and improve treatment satisfaction and compliance as well require fewer steps to titrate. Considering that overweight and obese patients usually require higher insulin doses because of insulin resistance, a higher initial dose of the basal insulin is feasible in overweight and obese patients with type 2 diabetes. However, safety is an important issue needing to be considered for higher initial

Full Text available with Trip Pro

2018 Advances in therapy Controlled trial quality: uncertain

53. Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. (PubMed)

Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. Because of the substantial increase in the occurrence of type 2 diabetes in the pediatric population and the medical complications of this condition, therapies are urgently needed that will achieve better glycemic control than standard medical management.To compare glycemic control in cohorts of severely obese adolescents with type 2 diabetes undergoing medical and surgical interventions.A secondary (...) from adolescents with severe obesity and type 2 diabetes who underwent treatment with metabolic or bariatric surgery in the Teen-LABS study or medical therapy in the TODAY study were compared.Teen-LABS participants underwent a primary bariatric surgical procedure; TODAY participants were randomized to receive metformin therapy alone or in combination with rosiglitazone or an intensive lifestyle intervention; insulin therapy was given in cases of progression of disease.Glycemic control, body mass

2018 JAMA pediatrics Controlled trial quality: uncertain

54. Timing the Discussion of Anti-Obesity Medications during Obesity Treatment (PubMed)

Timing the Discussion of Anti-Obesity Medications during Obesity Treatment 27588897 2018 11 13 1930-739X 24 10 2016 10 Obesity (Silver Spring, Md.) Obesity (Silver Spring) Timing the discussion of antiobesity medications during obesity treatment. 2027-8 10.1002/oby.21614 Rebello Candida J CJ Clinical Trials, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. O'Neil Patrick M PM Department of Psychiatry and Behavioral Sciences, Medical (...) University of South Carolina, Charleston, South Carolina, USA. Horn Deborah B DB Department of Surgery, Center for Obesity Medicine and Metabolic Performance, University of Texas, Bellaire, Texas, USA. Greenway Frank L FL Clinical Trials, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA. frank.greenway@pbrc.edu. eng P50 AT002776 AT NCCIH NIH HHS United States T32 AT004094 AT NCCIH NIH HHS United States Editorial 2016 09 02 United States Obesity (Silver

Full Text available with Trip Pro

2016 Obesity (Silver Spring, Md.)

55. Obesity medications reduce total body weight by 3-9% compared with placebo, when combined with lifestyle changes. (PubMed)

Obesity medications reduce total body weight by 3-9% compared with placebo, when combined with lifestyle changes. 24842056 2015 05 21 2018 12 02 1468-9618 18 1 2015 Jan Evidence-based nursing Evid Based Nurs Obesity medications reduce total body weight by 3-9% compared with placebo, when combined with lifestyle changes. 29-30 10.1136/eb-2014-101785 Gadde Kishore M KM Duke University Medical Center, Durham, North Carolina, USA. Yancy William S WS Jr Duke University Medical Center, Durham, North (...) Carolina, USA Veterans Affairs Medical Center, Durham, North Carolina, USA. eng Journal Article Comment 2014 05 19 England Evid Based Nurs 9815947 1367-6539 0 Anti-Obesity Agents IM N JAMA. 2014 Jan 1;311(1):74-86 24231879 Anti-Obesity Agents therapeutic use Humans Life Style Obesity drug therapy Clinical Pharmacology Nutrition & Dietetics 2014 5 21 6 0 2014 5 21 6 0 2015 5 23 6 0 ppublish 24842056 eb-2014-101785 10.1136/eb-2014-101785

Full Text available with Trip Pro

2015 Evidence-Based Nursing Controlled trial quality: predicted high

56. Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. (PubMed)

Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. The DSM 5 modified the medical exclusion criterion from DSM-IV, which now allows for a diagnosis of social anxiety disorder (SAD) to be given if the fears are related only to the medical condition (e.g., obesity) yet cause significant impairment or distress.To examine this modification, the current study compared bariatric surgery candidates with DSM-IV SAD (n=135), modified SAD (...) (clinically significant social fears related to obesity only; n=40), and no history of Axis I disorders (n=616) on variables related to pre-surgical problematic eating behaviors, body image dissatisfaction, functional impairment, and other characteristics related to bariatric surgery. Participants were referred by their surgeon for a psychiatric evaluation as part of the clearance process, and completed a comprehensive, semi-structured diagnostic interview and self-report measures.There were several

2017 Journal of Affective Disorders

57. Obesity: When to consider medication. (PubMed)

Obesity: When to consider medication. These 4 cases illustrate how weight loss drugs--including the 4 newest--can be integrated into a treatment plan that includes diet, exercise, and behavior modification.

2017 Journal of Family Practice

58. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. (PubMed)

US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Obesity is now the most prevalent chronic disease in the United States, which amounts to an estimated $147 billion in health care spending annually. The Affordable Care Act (ACA) enacted in 2010 included provisions for private and public health insurance plans that expanded coverage for lifestyle/behavior modification and bariatric surgery for the treatment of obesity. Pharmacotherapy (...) , however, has not been included despite their evidence-based efficacy. We set out to investigate the coverage of Food and Drug Administration-approved medications for obesity within Medicare, Medicaid and ACA-established marketplace health insurance plans.We examined coverage for phentermine, diethylpropion, phendimetrazine, Benzphentamine, Lorcaserin, Phentermine/Topiramate (Qysmia), Liraglutide (Saxenda) and Buproprion/Naltrexone (Contrave) among Medicare, Medicaid and marketplace insurance plans

Full Text available with Trip Pro

2017 International Journal of Obesity

59. The Impact of Obesity on Medical Care Costs and Labor Market Outcomes in the US. (PubMed)

The Impact of Obesity on Medical Care Costs and Labor Market Outcomes in the US. The prevalence of obesity has risen dramatically in most countries of the world, and the economic consequences of obesity are not well understood.We analyzed data from the Medical Expenditure Panel Survey (MEPS) for 2001-2015 and estimated the percentage of healthcare costs that were associated with adult obesity, both for the US as a whole and for the most populous states. We also reviewed the literature (...) on the impact of obesity on economic outcomes such as medical care costs, employment, and wages.The percent of US national medical expenditures devoted to treating obesity-related illness in adults rose from 6.13% in 2001 to 7.91% in 2015, an increase of 29%. Substantial differences existed across states; in 2015, some states (AZ, CA, FL, NY) devoted 5%-6% of medical expenditures to obesity, whereas others (NC, OH, WI) spent >12% of all healthcare dollars on obesity. A review of previous literature

2017 Clinical Chemistry

60. Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome. (PubMed)

Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome. Bariatric surgery, incretin-based therapy (glucagon-like peptide-1 analogues), and sodium-glucose co-transporter 2 (SGLT2) inhibitors have antidiabetic properties in morbidly obese patients. However, their comparative efficacy in treating type 2 diabetes mellitus (T2DM) in class I obese patients specifically in Indian has not been studied yet. This study evaluates (...) and compares the efficacy and side effect of surgical and advanced medical management of T2DM in class I obese patients.T2DM patients with body mass index ranging from 30 to 35 kg/m2 and with a median duration of 3 years and HbA1c level >7.5% were recruited for the study. Selection of treatment option that is bariatric surgery, GLP-1 analogues and SGLT2 inhibitor, was kept on patient's choice. Each group had 30 patients after 12 months of follow-up. Fasting plasma glucose (FPG), HbA1c, and lipid profile

2017 Obesity Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>